AIM ImmunoTech
Price & Volume
Stats
See more52W Range | $0.12-$0.62 |
Market Cap | $9.5M |
Shares Short | 914,816 |
Financials
See moreRevenue (12 Mos) | $190,000 |
Revenue Growth (YoY) | -23.9% |
Gross Profit (12 Mos) | $154,000 |
Diluted EPS | -$0.47 |
News
See moreYahoo Finance • 2 years ago
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Yahoo Finance • 2 years ago
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Yahoo Finance • 2 years ago
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
Yahoo Finance • 3 years ago
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
About
CEO | Mr. Thomas K. Equels Esq., J.D., M.S. |
Address | 2117 SW Highway 484, Ocala, FL, United States, 34473 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 26 |
